Real-world impact of fremanezumab on migraine symptoms and resource utilization in the United States

Real-world impact of fremanezumab on migraine symptoms and resource utilization in the United States

Abstract Background Fremanezumab, a fully humanized monoclonal antibody (IgG2Δa) that selectively targets calcitonin gene-related peptide (CGRP), is approved for migraine prevention in adults. Real-world data on the effectiveness of fremanezumab are limited. This retrospective, observational cohort...

Full description

Bibliographic Details
Main Authors: Peter McAllister, Lois Lamerato, Lynda J. Krasenbaum, Joshua M. Cohen, Krishna Tangirala, Stephen Thompson, Maurice Driessen, Julian Casciano, Zenobia Dotiwala, Alexander Mauskop
Format: Article
Language:English
Published: BMC 2021-12-01
Series:The Journal of Headache and Pain
Subjects:
Migraine
Fremanezumab
Health care resource utilization
Migraine pain intensity
Headache frequency
Real-world efficacy
Online Access:https://doi.org/10.1186/s10194-021-01358-9

Internet

https://doi.org/10.1186/s10194-021-01358-9

Similar Items